Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celcuity Inc CELC

Healthcare Biotechnology
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes... see more

Recent & Breaking News (NDAQ:CELC)

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

Accesswire December 7, 2022

Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium

Accesswire November 22, 2022

Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

Accesswire November 10, 2022

Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Accesswire November 10, 2022

Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call

Accesswire November 3, 2022

Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

Accesswire September 14, 2022

Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Accesswire August 11, 2022

Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call

Accesswire August 4, 2022

Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Accesswire August 3, 2022

Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

Accesswire July 18, 2022

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

Accesswire May 26, 2022

Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

Accesswire May 16, 2022

Celcuity Inc. Announces $100 Million Private Placement

Accesswire May 16, 2022

Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

Accesswire May 9, 2022

Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

Accesswire April 5, 2022

Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

Accesswire March 23, 2022

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call

Accesswire March 16, 2022

Celcuity to Participate in the Cowen 42nd Annual Health Care Conference

Accesswire March 2, 2022

Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update

Accesswire January 18, 2022

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium

Accesswire December 10, 2021